Shares of Arcus Biosciences, Inc. (NYSE:RCUS – Get Rating) have earned an average recommendation of “Moderate Buy” from the ten research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year target price […]
Arcus Biosciences, Inc. (NYSE:RCUS – Get Rating) was down 3% during mid-day trading on Tuesday . The stock traded as low as $19.85 and last traded at $19.92. Approximately 194,691 shares were traded during trading, a decline of 81% from the average daily volume of 1,036,818 shares. The stock had previously closed at $20.54. Analysts […]
Arcus Biosciences (NYSE:RCUS – Get Rating) had its target price hoisted by Citigroup from $40.00 to $41.00 in a research note published on Friday morning, The Fly reports. Several other research firms also recently weighed in on RCUS. Mizuho restated a buy rating and set a $51.00 price objective on shares of Arcus Biosciences in […]
AXQ Capital LP acquired a new position in Arcus Biosciences, Inc. (NYSE:RCUS – Get Rating) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 11,490 shares of the company’s stock, valued at approximately $238,000. A number of other hedge funds and other institutional investors […]
Sectoral Asset Management Inc. lifted its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Get Rating) by 5.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 238,482 shares of the company’s stock after purchasing an additional 11,450 […]